SEC Form 4 · accession 0001104659-17-008624
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McDonough
Officer — President & CEO · Director
Period of report
Feb 9, 2017
Accepted (ET)
Feb 13, 2017 · 4:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 9, 2017 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
| Stock Option (Right to Buy)F3 | $5.67 | Feb 9, 2017 | A | 100,000 | A | — | Feb 8, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2The restricted stock units vest in three equal annual installments beginning on February 9, 2018.
- F3The stock option vests in 48 monthly installments commencing February 9, 2017.